A Molecular Modeling Study of the Hydroxyflutamide Resistance Mechanism Induced by Androgen Receptor Mutations

Hydroxyflutamide (HF), an active metabolite of the first generation antiandrogen flutamide, was used in clinic to treat prostate cancer targeting androgen receptor (AR). However, a drug resistance problem appears after about one year’s treatment. AR T877A is the first mutation that was found to caus...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hong-Li, Zhong, Hai-Yang, Song, Tian-Qing, Li, Jia-Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618476/
https://www.ncbi.nlm.nih.gov/pubmed/28832499
http://dx.doi.org/10.3390/ijms18091823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618476/
https://www.ncbi.nlm.nih.gov/pubmed/28832499
http://dx.doi.org/10.3390/ijms18091823

Ejemplares similares